← All trials
NCT04692623
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2021
- Primary completion
- Mar 15, 2021
- Completion date
- Apr 1, 2021
- First posted
- Jan 5, 2021
- Last posted
- Jun 8, 2021
- Enrollment
- 25
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Shaheed Zulfiqar Ali Bhutto Medical UniversityLead sponsor
- Khyber Medical University PeshawarCollaborator
- Shaheed Zulfiqar Ali Bhutto Medical UniversityReponsible party - principal investigator
- Benazir Bhutto Hospital, RawalpindiStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.